[go: up one dir, main page]

BR9908953A - Utilização de cabergolina no tratamento da sìndrome de pernas agitadas (sìndrome de ekbom) - Google Patents

Utilização de cabergolina no tratamento da sìndrome de pernas agitadas (sìndrome de ekbom)

Info

Publication number
BR9908953A
BR9908953A BR9908953-0A BR9908953A BR9908953A BR 9908953 A BR9908953 A BR 9908953A BR 9908953 A BR9908953 A BR 9908953A BR 9908953 A BR9908953 A BR 9908953A
Authority
BR
Brazil
Prior art keywords
syndrome
cabergoline
treatment
ekbom
restless legs
Prior art date
Application number
BR9908953-0A
Other languages
English (en)
Inventor
Peter Schueler
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of BR9908953A publication Critical patent/BR9908953A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

<B>UTILIZAçãO DE CABERGOLINA NO TRATAMENTO DA SìNDROME DE PERNAS AGITADAS (SìNDROME DE EKBOM) <D> A presente invenção provê o uso de cabergolina e outros agentes para o tratamento da síndrome de pernas agitadas (síndrome de Ekbom) (RLS).
BR9908953-0A 1998-03-27 1999-03-24 Utilização de cabergolina no tratamento da sìndrome de pernas agitadas (sìndrome de ekbom) BR9908953A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7963998P 1998-03-27 1998-03-27
PCT/US1999/004269 WO1999048484A2 (en) 1998-03-27 1999-03-24 Use of cabergoline in the treatment of restless legs syndrome

Publications (1)

Publication Number Publication Date
BR9908953A true BR9908953A (pt) 2000-12-05

Family

ID=22151836

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9908953-0A BR9908953A (pt) 1998-03-27 1999-03-24 Utilização de cabergolina no tratamento da sìndrome de pernas agitadas (sìndrome de ekbom)

Country Status (23)

Country Link
US (1) US6114326A (pt)
EP (1) EP1066038B1 (pt)
JP (1) JP2002507562A (pt)
KR (1) KR100597517B1 (pt)
CN (1) CN1303286A (pt)
AT (1) ATE313326T1 (pt)
AU (1) AU747751B2 (pt)
BR (1) BR9908953A (pt)
CA (1) CA2320204A1 (pt)
CZ (1) CZ297284B6 (pt)
DE (1) DE69929041T2 (pt)
DK (1) DK1066038T3 (pt)
EA (1) EA002554B1 (pt)
ES (1) ES2255255T3 (pt)
HU (1) HUP0101954A3 (pt)
IL (1) IL138522A0 (pt)
NO (1) NO20004799L (pt)
NZ (1) NZ507176A (pt)
PL (1) PL343593A1 (pt)
SK (1) SK13312000A3 (pt)
TR (1) TR200002759T2 (pt)
WO (1) WO1999048484A2 (pt)
ZA (1) ZA200004452B (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
ES2412409T3 (es) 1997-12-22 2013-07-11 Euro-Celtique S.A. Forma farmacéutica para dosificación oral que comprende una combinación de un agonista opiáceo y un antagonista opiáceo
US6477408B1 (en) * 2000-03-07 2002-11-05 Northwestern University Analysis of muscular activity in neonatal animals to screen for mutations and/or drugs that alter sleep and wake states
GB0007308D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Process for preparing crystalline form | of cabergoline
GB0007309D0 (en) * 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form V|| of cabergoline
US6426713B1 (en) * 2000-07-05 2002-07-30 Cirrus Logic, Inc. Independent control of calibration registers in a multi channel A-D converter
DE10066158B4 (de) * 2000-08-24 2007-08-09 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung des Restless-Legs-Syndroms
DE10053397A1 (de) * 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
AR031152A1 (es) 2000-10-31 2003-09-10 Upjohn Co Tratamientos nuevos para el sindrome de piernas inquietas
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
US20020123503A1 (en) * 2000-12-21 2002-09-05 Malcolm Ross Cabergoline pharmaceutical compositions and methods of use thereof
JP4453254B2 (ja) * 2001-03-30 2010-04-21 東レ株式会社 レストレス・レッグズ症候群治療薬
US20030065002A1 (en) 2001-05-11 2003-04-03 Endo Pharmaceuticals, Inc. Abuse-resistant controlled-release opioid dosage form
US20030134844A1 (en) * 2001-10-31 2003-07-17 Pfizer Inc. Nicontinic acetylcholine receptor antagonists in the treatment of restless legs syndrome
US20030176822A1 (en) * 2002-03-12 2003-09-18 Morgenlander Joel C. Method of treating restless leg syndrome
EP1492505B1 (en) 2002-04-05 2015-06-03 Euro-Celtique S.A. Pharmaceutical preparation containing oxycodone and naloxone
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
JP4498140B2 (ja) 2002-08-30 2010-07-07 協和発酵キリン株式会社 行動障害治療剤
CA2538802C (en) 2003-09-17 2015-01-27 Xenoport, Inc. Treating or preventing restless legs syndrome using prodrugs of gaba analogs
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1604667A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
KR20060030175A (ko) * 2004-10-05 2006-04-10 경북대학교 산학협력단 무정위성 운동 치료용 약학조성물
GEP20105052B (en) * 2005-01-28 2010-07-26 Euro Celtique Sa Alcohol resistant dosage forms
EP1695700A1 (en) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
WO2007089335A2 (en) * 2005-12-29 2007-08-09 Lexicon Pharmaceutical Inc. Multicyclic amino acid derivatives and methods of their use
MX2008012781A (es) * 2006-04-03 2008-10-14 Teva Pharma Uso de rasagilina para el tratamiento de sindrome de piernas inquietas.
WO2008046149A1 (en) * 2006-10-17 2008-04-24 Biologic Health Solutions Pty Ltd Herbal compositions for the prevention or treatment of restless leg syndrome
EP1952813A1 (en) * 2007-02-01 2008-08-06 Ferring International Center S.A. Medicament for the treatment of endometriosis
EP1987815A1 (en) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
US7939665B2 (en) 2007-05-04 2011-05-10 Apotex Pharmachem Inc. Efficient process for the preparation of cabergoline and its intermediates
EP2083008A1 (en) * 2007-12-07 2009-07-29 Axxonis Pharma AG Ergoline derivatives as selective radical scavengers for neurons
BRPI1006186A2 (pt) 2009-03-10 2016-08-23 Euro Celtique Sa composições farmaceuticas de liberação imediata compreedendo oxicodona e naloxona
RU2701731C2 (ru) 2009-04-01 2019-10-01 Биал-Портела Энд Ка, С.А. Фармацевтические препараты, содержащие производные нитрокатехина, и способы их получения
US8690933B2 (en) * 2009-08-31 2014-04-08 Brigham Young University System and method for treating symptoms of restless legs syndrome
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
JP2016525138A (ja) 2013-07-23 2016-08-22 ユーロ−セルティーク エス．エイ． 疼痛および腸内ディスバイオシスをもたらす疾患および／または腸内細菌移行に対するリスクを高める疾患に罹患している患者における痛みの治療への使用のためのオキシコドンおよびナロキソンの組み合わせ
PL232974B1 (pl) * 2015-12-09 2019-08-30 Ofta Spolka Z Ograniczona Odpowiedzialnoscia Zastosowanie agonistów receptorów dopaminergicznych typu 2 w leczeniu schorzeń oczu wywołanych przez podwyższony poziom śródbłonkopochodnego czynnika wzrostu naczyń
US11103691B2 (en) 2019-10-03 2021-08-31 Noctrix Health, Inc. Peripheral nerve stimulation for restless legs syndrome
WO2018129351A1 (en) 2017-01-05 2018-07-12 Shriram Raghunathan Restless leg syndrome or overactive nerve treatment
JP2022551604A (ja) 2019-10-03 2022-12-12 ノクトリックス ヘルス インコーポレイテッド むずむず脚症候群のための末梢神経刺激

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526892A (en) * 1981-03-03 1985-07-02 Farmitalia Carlo Erba, S.P.A. Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas
US5496836A (en) * 1994-05-05 1996-03-05 Mount Sinai School Of Medicine Of The City University Of New York Use of famotidine and related compounds in the treatment of movement disorders

Also Published As

Publication number Publication date
EP1066038A2 (en) 2001-01-10
AU3353199A (en) 1999-10-18
NZ507176A (en) 2003-09-26
DK1066038T3 (da) 2006-04-24
KR20010052222A (ko) 2001-06-25
ZA200004452B (en) 2002-02-27
WO1999048484A2 (en) 1999-09-30
PL343593A1 (en) 2001-08-27
NO20004799D0 (no) 2000-09-26
AU747751B2 (en) 2002-05-23
EA002554B1 (ru) 2002-06-27
WO1999048484A3 (en) 1999-11-25
CZ20003419A3 (cs) 2002-01-16
ES2255255T3 (es) 2006-06-16
US6114326A (en) 2000-09-05
NO20004799L (no) 2000-10-11
CA2320204A1 (en) 1999-09-30
JP2002507562A (ja) 2002-03-12
DE69929041D1 (de) 2006-01-26
CN1303286A (zh) 2001-07-11
CZ297284B6 (cs) 2006-10-11
KR100597517B1 (ko) 2006-07-10
SK13312000A3 (sk) 2001-05-10
EP1066038B1 (en) 2005-12-21
TR200002759T2 (tr) 2001-02-21
HUP0101954A3 (en) 2002-09-30
IL138522A0 (en) 2001-10-31
DE69929041T2 (de) 2006-07-20
ATE313326T1 (de) 2006-01-15
HUP0101954A2 (hu) 2001-12-28
EA200000994A1 (ru) 2001-02-26

Similar Documents

Publication Publication Date Title
BR9908953A (pt) Utilização de cabergolina no tratamento da sìndrome de pernas agitadas (sìndrome de ekbom)
IL222002B (en) A preparation of taxane for the treatment of cancer, restenosis and retinopathy
BR9706968A (pt) Uso de antagonistas de alfa-ppar e gama-ppar para o tratamento de sindrome x
PT755249E (pt) Utilizacao de inibidores da reaccao de maillard para o tratamento de doenca com base em amiloidose
BR9400626A (pt) Artigo absorvente, almofada para incontinência urinária, estrutura absorvente e artigo absorvente
DK1039912T3 (da) Angiostatiske midler og præparater til behandling af GLC1A-glaukom
DE60032568D1 (de) Positionierungsapparat und damit versehener lithographischer Apparat
SG148031A1 (en) Use of cci-779 as an antineoplastic agent
ATE205391T1 (de) Nimesulid zur aüsserlichen anwendung
PT1010688E (pt) 2-fenil-1-(3,4-di-hidroxi-5-nitrofenil)-1-etanonas substituidas seu uso no tratamento de algumas perturbacoes do sistema nervoso central e periferico e formulacoes do sistema nervoso central e periferico e formulacoes farmaceuticas que as contem
ID21863A (id) Senyawa kinolin dan kinazolin yangberguna dalam terapi, khususnya dalam pengobatan heperplasia prostatik jinak
IS5504A (is) Samsetning virk við meðhöndlun á getuleysi
CA2408541A1 (en) Treating eczema and/or psoriasis
NO20000969L (no) Ftalazinderivater og midler for erektil dysfunksjon
ID24184A (id) Obat untuk perawatan disfungsi ereksi
ZA98420B (en) Use of pramipexole in the treatment of restless legs syndrome.
AU5388299A (en) Antibodies for use in targeted and temporary treatment of humans and animals
DE69426986D1 (de) Behandlung von laminitis
DE60106740D1 (de) Hydrazid und alkoxyamid angiogeneseinhibitoren
GB9723824D0 (en) Cytostatic agents
IT237515Y1 (it) Lettino trasportabile particolarmente studiato per massaggi e perfisioterapisti
KR940025061U (ko) 분체수송 및 폐수처리용 브로와(blower)
ITMS940006A0 (it) Trattamento antitarlo,igienizzante,disinfestante,per mobili,tessuti e oggetti usati in genere
UA25095A (uk) Ліhімеhт для лікуваhhя каhдидозhого і змішаhого вульвовагіhіту
UA43511C2 (en) Method for treating intracellular infections

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL: A61K 31/48, A61K 25/14

Ipc: A61K 31/48 (2007.10), A61P 25/14 (2007.10)

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ART. 8O DA LPI.